Eton Pharmaceuticals (NASDAQ:ETON) Issues Quarterly Earnings Results

Eton Pharmaceuticals (NASDAQ:ETON) released its quarterly earnings data on Thursday. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.28, FiscalAI reports. The company had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Record Q2 performance — Revenue rose 99% year over year to $37.6 million, adjusted EBITDA increased to $16.2 million, and net income reached $11.6 million versus a prior-year loss.
• Eton raised its 2026 outlook, now expecting revenue above $145 million versus prior guidance of more than $120 million, while increasing its adjusted EBITDA margin forecast to above 35% from above 30%.
• HEMANGEOL’s relaunch exceeded expectations, with approximately 95% of patients transitioned to Eton Cares by the end of June; management sees further growth from converting patients using off-label treatments and expects annual patients to exceed 10,000.
• The company added ASN-001, a late-stage topical hemangioma treatment that could address a larger patient population than HEMANGEOL and use the same commercial infrastructure. Eton plans to begin a $4 million bioavailability study shortly, submit an NDA in the second half of 2027, and potentially launch in 2028.
• Eton also advanced KHINDIVI, INCRELEX, Amglidia, DESMODA, Galzin, and ET-700, while adding U.S. rights to IMPAVIDO; however, several opportunities remain dependent on clinical studies, regulatory approvals, or future commercialization efforts.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock traded down $0.78 during midday trading on Thursday, hitting $40.80. 655,997 shares of the company’s stock were exchanged, compared to its average volume of 397,835. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -582.77 and a beta of 0.86. Eton Pharmaceuticals has a 12-month low of $14.27 and a 12-month high of $50.18. The firm’s 50 day simple moving average is $38.23 and its 200 day simple moving average is $28.20.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ETON. Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Craig Hallum boosted their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Canaccord Genuity Group started coverage on Eton Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $60.00 price target on the stock. Finally, Zacks Research lowered Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $54.50.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Eton reported second-quarter EPS of $0.43, well above the $0.15 analyst consensus, while revenue of $37.59 million exceeded expectations of $27.11 million. The results indicate stronger-than-anticipated operating performance. Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Positive Sentiment: HC Wainwright maintained its Buy rating and $65 price target, which remains above the stock’s recent trading level and signals continued confidence in Eton’s long-term growth prospects.
• Neutral Sentiment: Eton updated its fiscal 2026 earnings guidance, but the available report did not provide a specific EPS figure, limiting the immediate investment takeaway.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods, including fiscal 2026 to $0.52 from $0.68, fiscal 2027 to $1.28 from $1.83, fiscal 2028 to $2.23 from $3.50, fiscal 2029 to $4.25 from $5.85, and fiscal 2030 to $6.53 from $8.65. These cuts suggest analysts see a slower earnings ramp than previously expected and may be offsetting the quarterly beat. Eton Pharmaceuticals analyst estimates

Insider Transactions at Eton Pharmaceuticals

In related news, insider David Krempa sold 19,679 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total value of $619,298.13. Following the transaction, the insider owned 25,249 shares in the company, valued at $794,586.03. The trade was a 43.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 150,000 shares of company stock valued at $4,853,921 over the last ninety days. Corporate insiders own 16.49% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Millennium Management LLC grew its position in Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after buying an additional 217,042 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Eton Pharmaceuticals by 34.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after acquiring an additional 45,341 shares during the period. Jane Street Group LLC lifted its stake in shares of Eton Pharmaceuticals by 49.1% in the 1st quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock worth $1,245,000 after acquiring an additional 31,596 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Eton Pharmaceuticals by 114.5% in the second quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock valued at $3,457,000 after acquiring an additional 129,467 shares in the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $41,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.